A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Solid Tumors
Interventions: DRUG: MDK-703|DRUG: Checkpoint Inhibitor, Immune
Sponsor: Medikine, Inc.